Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy (vol 52, pg 298, 2022)

被引：0
|
作者：
Maesaka, K.
Sakamori, R.
Yamada, R.
Tahata, Y.
Imai, Y.
Ohkawa, K.
机构：
来源：
HEPATOLOGY RESEARCH | 2022年 / 52卷 / 07期
关键词：
D O I：
10.1111/hepr.13775
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：659 / 659
页数：1
相关论文
共 50 条
  • [41] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Tani, Joji
    Hirooka, Masashi
    Takaguchi, Koichi
    Atsukawa, Masanori
    Fukunishi, Shinya
    Itobayashi, Ei
    Tsuji, Kunihiko
    Tajiri, Kazuto
    Ochi, Hironori
    Ishikawa, Toru
    Yasuda, Satoshi
    Ogawa, Chikara
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Nishimura, Takashi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Shimada, Noritomo
    Tada, Fujimasa
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Ohama, Hideko
    Morishita, Asahiro
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Kosaka, Hisashi
    Imai, Michitaka
    Naganuma, Atsushi
    Nakamura, Shinichiro
    Koizumi, Yohei
    Matono, Tomomitsu
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (04) : 270 - 281
  • [42] Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices
    Fujimasa Tada
    Atsushi Hiraoka
    Toshifumi Tada
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Takeshi Hatanaka
    Satoru Kakizaki
    Noritomo Shimada
    Kazuhito Kawata
    Atsushi Naganuma
    Hisashi Kosaka
    Tomomitsu Matono
    Hidekatsu Kuroda
    Yutaka Yata
    Hideko Ohama
    Kazuhiro Nouso
    Asahiro Morishita
    Akemi Tsutsui
    Takuya Nagano
    Norio Itokawa
    Tomomi Okubo
    Taeang Arai
    Keisuke Yokohama
    Hiroki Nishikawa
    Michitaka Imai
    Yohei Koizumi
    Shinichiro Nakamura
    Hiroko Iijima
    Masaki Kaibori
    Yoichi Hiasa
    Takashi Kumada
    Journal of Gastroenterology, 2023, 58 : 1134 - 1143
  • [43] FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
    Casak, Sandra J.
    Donoghue, Martha
    Fashoyin-Aje, Lola
    Jiang, Xiaoping
    Rodriguez, Lisa
    Shen, Yuan-Li
    Xu, Yuan
    Jiang, Xiling
    Liu, Jiang
    Zhao, Hong
    Pierce, William F.
    Mehta, Shubhangi
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Pazdur, Richard
    Lemery, Steven J.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1836 - 1841
  • [44] The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients
    Aranda-Gutierrez, Alejandro
    Conde-Flores, Emilio
    Meraz-Brenez, Andres
    Escorza, Salvador
    Meneses-Medina, Monica I. Isabel
    Huitzil-Melendez, Fidel David
    de la Mora-Molina, Hector
    Rosas Camargo, Vanessa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] ASSESSING ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS WITH ESOPHAGEAL-GASTRIC VARICES
    Tada, Fujimasa
    Hiraoka, Atsushi
    Hatanaka, Takeshi
    Tada, Toshifumi
    Kakizaki, Satoru
    Kumada, Takashi
    GASTROENTEROLOGY, 2024, 166 (05) : S1730 - S1730
  • [46] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Changez, Mah I. Kan
    Khan, Maimoona
    Uzair, Muhammad
    Tahir, Muhammad Fawad
    Mohsin, Maryam
    Hussain, Amna Faiyaz
    Saqib, Vania
    Molani, Muhammad Khizer
    Ahmed, Aisha Habib
    Khalid, Saad
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 467 - 481
  • [47] Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Yano, Shigeki
    Kawaoka, Tomokazu
    Yamasaki, Shintaro
    Johira, Yusuke
    Kosaka, Masanari
    Shirane, Yuki
    Miura, Ryoichi
    Amioka, Kei
    Naruto, Kensuke
    Yamaoka, Kenji
    Fujii, Yasutoshi
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Miki, Daiki
    Tsuge, Masataka
    Teraoka, Yuji
    Kouno, Hirotaka
    Takaki, Shintaro
    Mori, Nami
    Tsuji, Keiji
    Oka, Shiro
    CANCERS, 2023, 15 (22)
  • [48] Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
    Kobayashi, Kojiro
    Nagai, Hidenari
    Matsui, Teppei
    Matsuda, Takahisa
    Higai, Koji
    ANTICANCER RESEARCH, 2023, 43 (10) : 4601 - 4609
  • [49] Safety of Upfront Locoregional Therapy in Conjunction with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
    Rodriguez-Russo, C.
    Wu, L.
    Bloom, J.
    Cohen, D.
    Buckstein, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E179 - E179
  • [50] Safety of Upfront Locoregional Therapy in Conjunction with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
    Rodriguez-Russo, Carlos
    Wu, Linda
    Bloom, Julie
    Hotca-Cho, Alexandra
    Hsieh, Kristin
    Stalbow, Lauren
    Cohen, Deirdre
    Buckstein, Michael
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (10): : S15 - S16
12345